Rchr
J-GLOBAL ID:202001008706029467   Update date: May. 14, 2024

Iida Keitaro

Iida Keitaro
Affiliation and department:
Job title: 研究員
Research theme for competitive and other funds  (9):
  • 2021 - 2024 去勢抵抗性前立腺癌における細胞間連絡機構を介した進展機序の解明と分子基盤
  • 2020 - 2023 エピゲノム酵素LSD1の新規阻害剤による骨転移の難治性疼痛に対する新規治療開発
  • 2018 - 2021 Theraputic effect of natural flavonoid on bladder cancer
  • 2017 - 2020 Molecular mechanisms for prostate cancer prevention induced by natural flavonoid
  • 2017 - 2020 Prognostic analysis of ADC level in MRI for localized bladder carcinoma patients.
Show all
Papers (132):
  • Toshiharu Morikawa, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Teruki Isobe, Yusuke Noda, Nobuhiko Shimizu, et al. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers. 2024. 16. 9
  • Teruki Isobe, Noriyasu Kawai, Maria Aoki, Toshiharu Morikawa, Masakazu Gonda, Nami Tomiyama, Takashi Nagai, Keitaro Iida, Toshiki Etani, Taku Naiki, et al. Late relapsing testicle cancer identified with isochromosome 12p (i12p) fluorescence in situ hybridization (FISH) analysis. Pathology international. 2024
  • Keitaro Iida, Taku Naiki, Toshiki Etani, Takashi Nagai, Yosuke Sugiyama, Teruki Isobe, Maria Aoki, Satoshi Nozaki, Yusuke Noda, Nobuhiko Shimizu, et al. Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma. Scientific reports. 2024. 14. 1. 2520-2520
  • Takashi Nagai, Taku Naiki, Yosuke Sugiyama, Toshiki Etani, Maria Aoki, Masakazu Gonda, Toshiharu Morikawa, Keitaro Iida, Nami Tomiyama, Ryosuke Ando, et al. A narrative review of peripheral blood parameters for urothelial carcinoma treated with systemic antitumor drugs. Translational Andrology and Urology. 2023. 12. 5. 790-801
  • 内木 拓, 内木 綾, 惠谷 俊紀, 永井 隆, 飯田 啓太郎, 青木 マリア, 権田 将一, 森川 敏治, 磯部 輝紀, 河合 憲康, et al. 前立腺発がん・進展予防を目的としたルテオリンを用いた臨床試験のための安全性の検証(Trial for the clinical application of luteolin for chemopreventive study of patients with prostate cancer). 日本泌尿器科学会総会. 2023. 110回. OP60-03
more...
MISC (40):
  • 森川敏治, 内木拓, 内木綾, 三村佳久, 青木マリア, 磯部輝紀, 権田将一, 冨山奈美, 清水伸彦, 野田祐介, et al. 転移巣切除を行った尿路上皮癌症例に関する検討. 日本癌治療学会学術集会(Web). 2022. 60th
  • 青木マリア, 内木拓, 磯部輝紀, 権田将一, 冨山奈美, 清水伸彦, 野田祐介, 永井隆, 惠谷俊紀, 飯田啓太郎, et al. 術前化学療法前後における骨格筋変化量は膀胱全摘症例の予後予測因子である. 日本癌治療学会学術集会(Web). 2022. 60th
  • Keitaro Iida, Taku Naiki, Aya Naiki-Ito, Takashi Nagai, Satoshi Nozaki, Toshiki Etani, Ryosuke Ando, Noriyasu Kawai, Takahiro Yasui. LUTEOLIN SUPPRESSES SQUAMOUS DIFFERENTIATION OF BLADDER CANCER AND CANCER GROWTH VIA REGULATION OF MAMMALIAN TARGET OF RAPAMYCIN PATHWAY. JOURNAL OF UROLOGY. 2020. 203. E5-E5
  • Taku Naiki, Aya Naiki-Ito, Hiroyuki Kato, Keitaro Iida, Toshiki Etani, Yuko Nagayasu, Shugo Suzuki, Yoriko Yamashita, Takahiro Yasui, Satoru Takahashi. MIR-8080 RECRUITMENT INHIBITS EXPRESSION OF ANDROGEN RECEPTOR SPLICING VARIANTS IN CASTRATION-RESISTANT PROSTATE CANCER. JOURNAL OF UROLOGY. 2020. 203. E218-E218
  • Taku Naiki, Aya Naiki-Ito, Toshiki Etani, Keitaro Iida, Ryosuke Ando, Takashi Nagai, Noriyasu Kawai, Satoru Takahashi, Takahiro Yasui. GPX2 PROMOTES THE DEVELOPMENT OF BLADDER CANCER WITH SQUAMOUS DIFFERENTIATION THROUGH APOPTOSIS CONTROL. JOURNAL OF UROLOGY. 2020. 203. E4-E4
more...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page